Bulk Manufacturer of Controlled Substances Application: Rhodes Technologies, 40567-40568 [2018-17605]
Download as PDF
<![CDATA[
40567
Federal Register / Vol. 83, No. 158 / Wednesday, August 15, 2018 / Notices
60. Courts cannot look beyond the
complaint in making the public interest
determination ‘‘unless the complaint
underlying the decree is drafted so
narrowly such that its entry would
appear ‘to make a mockery of judicial
power.’’’ Apple, 889 F. Supp. 2d at 631
(S.D.N.Y. 2012) (citing SBC Commc’ns,
489 F. Supp. 2d at 15).
In its 2004 amendments, Congress
made clear its intent to preserve the
practical benefits of utilizing consent
decrees in antitrust enforcement, adding
the unambiguous instruction that
‘‘[n]othing in this section shall be
construed to require the court to
conduct an evidentiary hearing or to
require the court to permit anyone to
intervene.’’ 15 U.S.C. § 16(e)(2); see also
U.S. Airways, 38 F. Supp. 3d at 75
(indicating that a court is not required
to hold an evidentiary hearing or to
permit intervenors as part of its review
under the Tunney Act). The language
wrote into the statute what Congress
intended when it enacted the Tunney
Act in 1974, as Senator Tunney
explained: ‘‘[t]he court is nowhere
compelled to go to trial or to engage in
extended proceedings which might have
the effect of vitiating the benefits of
prompt and less costly settlement
through the consent decree process.’’
119 Cong. Rec. 24, 598 (1973) (statement
of Sen. Tunney). Rather, the procedure
for the public interest determination is
left to the discretion of the court, with
the recognition that the court’s ‘‘scope
of review remains sharply proscribed by
precedent and the nature of Tunney Act
proceedings.’’ SBC Commc’ns, 489 F.
Supp. 2d at 11; see also Apple, 889 F.
Supp. 2d at 632 (‘‘[P]rosecutorial
functions vested solely in the executive
branch could be undermined by the
improper use of the APPA as an
antitrust oversight provision.’’) (citation
omitted). A court can make its public
interest determination based on the
competitive impact statement and
response to public comments alone.
U.S. Airways, 38 F. Supp. 3d at 75.3
VIII. DETERMINATIVE DOCUMENTS
There are no determinative materials
or documents within the meaning of the
APPA that were considered by the
United States in formulating the
proposed Final Judgment.
Dated: August 7, 2018
Respectfully submitted,
lllllllllllllllllllll
Lowell R. Stern
United States Department of Justice,
Antitrust Division, Media, Entertainment &
Professional Services Section, 450 Fifth
Street, N.W., Suite 4000, Washington, DC
20530, Telephone: (202) 514–3676,
Facsimile: (202) 514–7308, E-mail:
lowell.stern@usdoj.gov
Attorney for Plaintiff United States
[FR Doc. 2018–17521 Filed 8–14–18; 8:45 am]
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Rhodes
Technologies
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 15, 2018.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated
his authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
delegated to the Assistant Administrator
of the DEA Diversion Control Division
(‘‘Assistant Administrator’’) pursuant to
section 7 of 28 CFR part 0, appendix to
subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on June
28th, 2018, Rhodes Technologies, 498
Washington Street, Coventry, Rhode
Island 02816 applied to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
daltland on DSKBBV9HB2PROD with NOTICES
Controlled substance
Drug code
Marihuana ......................................................................................................................................................................
Tetrahydrocannabinols ..................................................................................................................................................
Dihydromorphine ............................................................................................................................................................
Methylphenidate .............................................................................................................................................................
Codeine ..........................................................................................................................................................................
Dihydrocodeine ..............................................................................................................................................................
Oxycodone .....................................................................................................................................................................
Hydromorphone .............................................................................................................................................................
Hydrocodone ..................................................................................................................................................................
Levorphanol ...................................................................................................................................................................
Morphine ........................................................................................................................................................................
Oripavine ........................................................................................................................................................................
Thebaine ........................................................................................................................................................................
Oxymorphone ................................................................................................................................................................
Noroxymorpohone .........................................................................................................................................................
Tapentadol .....................................................................................................................................................................
3 See United States v. Enova Corp., 107 F. Supp.
2d 10, 17 (D.D.C. 2000) (noting that the ‘‘Tunney
Act expressly allows the court to make its public
interest determination on the basis of the
competitive impact statement and response to
comments alone’’); United States v. Mid-Am.
Dairymen, Inc., No. 73–CV–681–W–1, 1977–1 Trade
VerDate Sep<11>2014
18:28 Aug 14, 2018
Jkt 244001
Cas. (CCH) ¶ 61,508, at 71,980, *22 (W.D. Mo. 1977)
(‘‘Absent a showing of corrupt failure of the
government to discharge its duty, the Court, in
making its public interest finding, should . . .
carefully consider the explanations of the
government in the competitive impact statement
and its responses to comments in order to
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
7360
7370
9145
1724
9050
9120
9143
9150
9193
9220
9300
9330
9333
9652
9668
9780
Schedule
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
determine whether those explanations are
reasonable under the circumstances.’’); S. Rep. No.
93–298, at 6 (1973) (‘‘Where the public interest can
be meaningfully evaluated simply on the basis of
briefs and oral arguments, that is the approach that
should be utilized.’’).
E:\FR\FM\15AUN1.SGM
15AUN1
40568
Federal Register / Vol. 83, No. 158 / Wednesday, August 15, 2018 / Notices
The company plans to manufacture
the listed controlled substances in bulk
for conversion and sale to finished
dosage form manufacturers. In reference
to drug code 7360 and 7370, the
company plans to bulk manufacture a
synthetic CBD and
tetrahydrocannabinol. No other activity
for drug code 7360 and 7370 are
authorized for this registration.
Dated: August 3, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–17605 Filed 8–14–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1110–0067]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Revision of an
Existing Collection in Use Rap Back
Services Form (1–796)
Criminal Justice Information
Services Division, Federal Bureau of
Investigation, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice
(DOJ), Federal Bureau of Investigation
(FBI), Criminal Justice Information
Services (CJIS) Division, will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until
October 15, 2018.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Gerry Lynn Brovey, Supervisory
Information Liaison Specialist, Federal
Bureau of Investigation, Criminal Justice
Information Services Division, 1000
Custer Hollow Road; Clarksburg, WV
26306; phone: 304–625–4320 or email
glbrovey@ic.fbi.gov. Written comments
and/or suggestions can also be sent to
the Office of Management and Budget,
Office of Information and Regulatory
Affairs, Attention Department of Justice
Desk Officer, Washington, DC 20503 or
sent to OIRA_submissions@
omb.eop.gov.
daltland on DSKBBV9HB2PROD with NOTICES
SUMMARY:
Written
comments and suggestions from the
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
18:28 Aug 14, 2018
Jkt 244001
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Revision of an approved collection.
(2) Title of the Form/Collection: Rap
Back Services Form (1–796).
(3) Agency form number: The form
number is 1–796. Sponsoring
component: Department of Justice,
Federal Bureau of Investigation,
Criminal Justice Information Services
Division.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: This form is utilized
by authorized agencies to enroll
individuals in the Rap Back Service to
ensure the submitting agency is notified
when individuals in positions of trust
engage in criminal conduct or
individuals under the supervision of a
criminal justice agency commit
subsequent criminal acts.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 12
respondents will complete each form
within approximately 5 minutes.
(6) An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 60
total annual burden hours associated
with this collection.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
Planning Staff, Two Constitution
Square, 145 N Street NE, 3E.405A,
Washington, DC 20530.
Dated: August 10, 2018.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2018–17529 Filed 8–14–18; 8:45 am]
BILLING CODE 4410–02–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (NIJ) Docket No. 1750]
Body Armor Manufacturer Workshop
AGENCY:
National Institute of Justice,
Justice.
ACTION:
Notice.
The National Institute of
Justice (NIJ) is hosting a workshop for
body armor manufacturers to provide an
overview of draft NIJ Standard 0101.07,
Ballistic Resistance of Body Armor, and
draft NIJ Specification Threat Levels
and Associated Ammunition to Test
Equipment Intended to Protect U.S. Law
Enforcement Against Handguns and
Rifles. A preliminary outline of how the
NIJ Compliance Testing Program (CTP),
which manages conformity assessment
of body armor, will begin to phase out
use of NIJ Standard 0101.06 and phase
in the use of NIJ Standard 0101.07 in the
administration of the program over
approximately the next year will be
presented. The impact of the transition
on the Compliant Products List (CPL)
and Follow-up Inspection Testing (FIT)
of listed body armor models compliant
with NIJ Standard 0101.06 over a longer
period of time will also be discussed.
This will be an open forum and there
will opportunities for attendees to ask
questions. Space is limited at this
workshop, and as a result, only 100
participants will be allowed to register.
NIJ requests that each manufacturer
limit their representatives to no more
than two per organization. Exceptions to
this limit may occur, should space
allow. Participants planning to attend
are responsible for their own travel
arrangements. To register for the
workshop, please send an email to
bactp@justnet.org by 5:00 p.m. Eastern
time on September 7, 2018, and provide
the name of your company and the
names of the representatives who will
attend. A preliminary agenda will be
sent to registered attendees
approximately one week prior to the
workshop.
SUMMARY:
E:\FR\FM\15AUN1.SGM
15AUN1
]]>Agencies
[Federal Register Volume 83, Number 158 (Wednesday, August 15, 2018)]
[Notices]
[Pages 40567-40568]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-17605]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Rhodes
Technologies
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before October 15, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the
Controlled Substances Act to the Administrator of the Drug Enforcement
Administration (DEA), 28 CFR 0.100(b). Authority to exercise all
necessary functions with respect to the promulgation and implementation
of 21 CFR part 1301, incident to the registration of manufacturers,
distributors, dispensers, importers, and exporters of controlled
substances (other than final orders in connection with suspension,
denial, or revocation of registration) has been delegated to the
Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on June
28th, 2018, Rhodes Technologies, 498 Washington Street, Coventry, Rhode
Island 02816 applied to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana........................... 7360 I
Tetrahydrocannabinols............... 7370 I
Dihydromorphine..................... 9145 I
Methylphenidate..................... 1724 II
Codeine............................. 9050 II
Dihydrocodeine...................... 9120 II
Oxycodone........................... 9143 II
Hydromorphone....................... 9150 II
Hydrocodone......................... 9193 II
Levorphanol......................... 9220 II
Morphine............................ 9300 II
Oripavine........................... 9330 II
Thebaine............................ 9333 II
Oxymorphone......................... 9652 II
Noroxymorpohone..................... 9668 II
Tapentadol.......................... 9780 II
------------------------------------------------------------------------
[[Page 40568]]
The company plans to manufacture the listed controlled substances
in bulk for conversion and sale to finished dosage form manufacturers.
In reference to drug code 7360 and 7370, the company plans to bulk
manufacture a synthetic CBD and tetrahydrocannabinol. No other activity
for drug code 7360 and 7370 are authorized for this registration.
Dated: August 3, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-17605 Filed 8-14-18; 8:45 am]
BILLING CODE 4410-09-P
